{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:54:40Z","timestamp":1782485680799,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1006,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1124\/jpet.121.000881","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T03:35:12Z","timestamp":1643168112000},"page":"12-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody"],"prefix":"10.1016","volume":"381","author":[{"given":"Sujatha","family":"Muralidharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Njenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Garron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Bondensgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000881_bib1","doi-asserted-by":"crossref","first-page":"22342","DOI":"10.3390\/ijms151222342","article-title":"The signaling role of CD40 ligand in platelet biology and in platelet component transfusion","volume":"15","author":"Aloui","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.121.000881_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-0-387-70630-6_11","article-title":"TRAF proteins in CD40 signaling","volume":"597","author":"Bishop","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/jpet.121.000881_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.121.000881_bib4","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.185.12.2053","article-title":"A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction","volume":"185","author":"Carbone","year":"1997","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.121.000881_bib5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.121.000881_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.2003.026278","article-title":"The CD40\/CD40L costimulatory pathway in inflammatory bowel disease","volume":"53","author":"Danese","year":"2004","journal-title":"Gut"},{"key":"10.1124\/jpet.121.000881_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1124\/jpet.121.000881_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/eji.1830250335","article-title":"CD40 ligand is functionally expressed on human eosinophils","volume":"25","author":"Gauchat","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1124\/jpet.121.000881_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/365340a0","article-title":"Induction of human IgE synthesis in B cells by mast cells and basophils","volume":"365","author":"Gauchat","year":"1993","journal-title":"Nature"},{"key":"10.1124\/jpet.121.000881_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-065X.1996.tb00921.x","article-title":"The role of CD40 ligand in costimulation and T-cell activation","volume":"153","author":"Grewal","year":"1996","journal-title":"Immunol Rev"},{"key":"10.1124\/jpet.121.000881_bib11","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.4049\/jimmunol.178.5.2844","article-title":"CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help","volume":"178","author":"Hernandez","year":"2007","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.000881_bib12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.4049\/jimmunol.1200311","article-title":"Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease","volume":"189","author":"Huber","year":"2012","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.000881_bib13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/01.RES.0000070111.98158.6C","article-title":"CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation","volume":"92","author":"Inwald","year":"2003","journal-title":"Circ Res"},{"key":"10.1124\/jpet.121.000881_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/clinem\/dgz013","article-title":"A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.121.000881_bib15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/01.TP.0000116392.72152.75","article-title":"Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model","volume":"77","author":"Kanmaz","year":"2004","journal-title":"Transplantation"},{"key":"10.1124\/jpet.121.000881_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar6584","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","volume":"11","author":"Karnell","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1124\/jpet.121.000881_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.121.000881_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/978-0-387-89520-8_2","article-title":"Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges","volume":"647","author":"Law","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/jpet.121.000881_bib19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/j.1600-6143.2012.04054.x","article-title":"A novel monoclonal antibody to CD40 prolongs islet allograft survival","volume":"12","author":"Lowe","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1124\/jpet.121.000881_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-020-02372-z","article-title":"Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients","volume":"23","author":"Marken","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/jpet.121.000881_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ajt.15574","article-title":"Anti-CD40 antibody 2C10 binds to a conformational epitope at the CD40-CD154 interface that is conserved among primate species","volume":"20","author":"Michaels","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1124\/jpet.121.000881_bib22","doi-asserted-by":"crossref","first-page":"11138","DOI":"10.1038\/ncomms11138","article-title":"Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft","volume":"7","author":"Mohiuddin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.121.000881_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40 ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1124\/jpet.121.000881_bib24","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2008-08-175034","article-title":"CD40: Lord of the endothelial cell","volume":"112","author":"Phipps","year":"2008","journal-title":"Blood"},{"key":"10.1124\/jpet.121.000881_bib25","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1124\/jpet.121.000881_bib26","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","article-title":"Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice","volume":"185","author":"Robles-Carrillo","year":"2010","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.000881_bib27","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/jcph.1278","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases","volume":"58","author":"Schwabe","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.121.000881_bib28","doi-asserted-by":"crossref","first-page":"d1","DOI":"10.2741\/A170","article-title":"Immune regulation by CD40-CD40-L interactions","volume":"2","author":"van Kooten","year":"1997","journal-title":"Front Biosci"},{"key":"10.1124\/jpet.121.000881_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1124\/jpet.121.000881_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4049\/immunohorizons.1700069","article-title":"Requirement for CD40\/CD40L Interactions for Development of Autoimmunity Differs Depending on Specific Checkpoint and Costimulatory Pathways","volume":"2","author":"Voynova","year":"2018","journal-title":"Immunohorizons"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:16:09Z","timestamp":1739970969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524002556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0022356524002556"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000881","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s)","name":"copyright","label":"Copyright"}]}}